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Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused
by severe acute respiratory syndrome coronavirus SARS-COV-2. Aberrant innate
immunity response and cytokine storm are responsible for the syndrome. Apparently,
in asthmatic patients, the inadequate antiviral immune response and the tendency for
asthma exacerbation evoked by common respiratory viruses could explain increased
susceptibility to SARS-COV-2 infection. However, asthma has not been suggested to
be a risk factor in COVID-19 patients. Therefore, in asthmatic patients some potential
protective mechanisms against SARS-COV-2 have been hypothesized, like type 2
immune response, number of eosinophils, overproduction of mucus, and asthma
treatment, along with behavioral factors not strictly related to asthma, such as social
distancing, hygiene measures and wearing facemasks, that contribute to reduce the
individual susceptibility to SARS-COV-2 infection. In this mini-review, we will describe
the current literature regarding potential protective factors against COVID-19 in children
with asthma based on the evidence available so far.
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INTRODUCTION
Coronaviruses are a family of single-stranded RiboNucleoid Acid (RNA) viruses able to infect
humans, other mammals, and avian species. Human coronaviruses usually cause seasonal and
mild respiratory tract infections which spread predominantly by droplets, aerosols and contact
transmission, even though severe acute respiratory syndrome coronavirus (SARS-CoV), Middle
East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2, which have appeared over
the past 20 years, are considered highly pathogenic (1, 2). The infection caused by SARS-CoV-2, also
recognized as Coronavirus Disease 2019 (COVID-19), began inWuhan (China) and quickly spread
all over the globe, so that this outbreak was proclaimed a pandemic on March 11, 2020, by the
World Health Organization (3). COVID-19 presents with general and respiratory symptoms (fever
associated with fatigue, myalgia, anorexia, dry cough, dyspnea), from mild to severe, which can be
associated with a so-called “cytokine storm” (1, 2). Indeed, some patients show fast progression
of the disease, ending in acute lung damage and multiple organ failure, whereas many infected
people show mild or no symptoms. The median incubation period is approximately 5.1 days with
97.5% of symptoms becoming evident within 11.5 days (2). Early evidence from China and Italy
indicated that children have less severe clinical manifestations than adults, with lower infection
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rates and reduced hospital admissions due to a lower incidence
of severe disease and minimal mortality (4). Based on the
available literature, it is believed that children could be spared
from COVID-19 likely due to the highly expressed thymic
repertoire and efficiently activated immune response against
SARS-COV-2 (5). Out of the total cases, children accounted
for only 1.2% in Italy, 5% in the USA and 2% in China (6).
Clinical manifestations, laboratory tests and radiological findings
in children with COVID-19 are described in Table 1. One severe
complication of SARS-CoV-2 infection in children is a Kawasaki-
like disease also known “multi-system inflammatory syndrome
in children” (MIS-C). MIS-C derives from the unregulated
release of proinflammatory cytokines and tissue damage–related
enzymes that are responsible for multi-organ and/or multi-
system failure (6). Because of generally low morbidity in children
with COVID-19, it is difficult to ascertain the impact of
SARS-CoV-2 on this population (7). Several factors have been
hypothesized to offer an explanation on the low severity of the
disease in the pediatric age group. First, seasonal coronaviruses
may give a protective immune response toward SARS-CoV-2
(8). Second, children show low expression or function of the
angiotensin-converting enzyme 2 (ACE 2) receptor (9). Third,
in children there are “innate” B cells, called immune naïve cells,
that respond to novel antigens, producing effective immune
responses against the pathogen and possibly contributing to
the lower pathogenicity of SARS-COV-2 in the pediatric age
(10). Fourth, in the pediatric age immature B cells secrete anti-
inflammatory cytokines such as IL-10, which may contribute to
reducing the immune-mediated tissue damage (11). Moreover,
the lower severity of COVID-19 in children with respect to adults
could be explained by a stronger innate immune response and by
the lack of co-morbid conditions in most subjects (6). Many risk
factors such as diabetes, obesity and cardiovascular diseases are
associated with COVID-19. Surprisingly, despite being a chronic
respiratory disease, asthma would not seem a risk factor for
COVID-19 either in childhood or in adulthood (1, 2, 12). In
this mini-review, we will describe the current literature regarding
protective factors against COVID-19 in children with asthma
based on the evidence available at this time.
TABLE 1 | Clinical manifestations, laboratory, and radiologic findings in children with COVID-19.
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SARS-COV-2 necessitates two proteins for entry into the host
cell. The virus attaches to the ACE 2 receptor; subsequently,
the host trans-membrane protease serine 2 (TMPRSS2) splits
up the spike protein, expressed on the viral envelope, into
two segments, allowing fusion of SARS-COV-2 to the cellular
membrane and its penetration into the cell. The binding of SARS-
CoV-2 to ACE 2 receptors produces a marked down-regulation
of these molecules, whose protective effects on the human body
have been recognized. The loss of such protective effects could
result in interstitial fibrosis, endothelial dysfunction, marked
inflammation, oxidative stress and enhanced coagulation (13). In
fact, after its entry into the host cells, the activated innate immune
response prompts release of pro-inflammatory cytokines, which
recruit effector cells like neutrophils, macrophages, etc. In the
context of the adaptive immune response, antigen-presenting
cells (APCs) present viral antigens to T cells, eliciting
differentiation from immature cells to mature cells (Cytotoxic
T cells and Natural Killer cells) that might contribute to
killing virus-infected cells. In particular, once the virus is inside
the cells, viral peptides are presented through Class I Major
Histocompatibility Complex (MHC) proteins to CD8+ cytotoxic
T cells (CD8+ T cells). Activated CD8+ T cells clonally expand
and differentiate into virus-specific effector and memory T cells.
The virus-infected cells are killed by CD8+T cells. Dendritic cells
and macrophages (APCs) recognize the virus and its particles
and present them to CD4+ T cells through MHC-Class-II
molecules. The viruses can activate B lymphocytes that can
interact with CD4+ T cells. In the first week following symptoms,
the primary antibody response determines an increased amount
of virus-specific IgM followed by production of virus-specific
IgGs (14). If the adaptive immune responses are insufficient,
innate immune responses can be reinforced through a cytokine
storm that is responsible for severe multi-organ damage (1, 2).
In case of low-dose virus infection, efficient T- and B-cells
responses and neutralizing antibodies could lead to rapid viral
clearance. By contrast, high-dose virus exposure may account for
severe disease and delayed viral clearance. This can be attributed
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to lymphopenia, which determines inadequate T- and B-cells
responses, eventually followed by a cytokine storm and multi-
organ failure (14).
PATHOGENESIS OF ASTHMA
Asthma is a respiratory disease characterized by chronic
inflammation of the airways with bronchial hyper-responsiveness
to several stimuli, mucus overproduction, recurrent episodes
of wheezing, respiratory distress, and cough, associated with
reversible airway obstruction. Asthma is one of the most
common chronic diseases worldwide, affecting more than 300
million individuals, and the incidence is growing, particularly
in developed countries (15). Asthma remains one of the
highest causes for school absence and hospital admissions,
imposing a high socioeconomic burden, and impairing quality
of life of children and their families (16, 17). Allergic asthma
is the most common type, where exposure to allergens in
sensitized subjects specifically triggers a type 2 (T2) inflammatory
response (1, 2). Because of the tendency for disease exacerbation
elicited by common respiratory viruses including Rhinovirus,
Respiratory Syncytial Virus, Influenza virus, Parainfluenza virus,
Adenovirus, human Bocavirus, and Coronaviruses (18) and a
deficient antiviral immune response that is evident in asthmatic
patients (2, 19, 20), the latter should potentially have increased
vulnerability to SARS-COV-2 infection. This could be sustained
by the deficient type I Interferon (IFN) responses observed in
patients with severe asthma. In particular, activated T helper
(Th) 2 cells secrete Interleukin (IL)-4/13 and IL-5, which are
responsible for activation of other inflammatory cells, including
eosinophils (21). Eosinophils organize the immune response
against respiratory viruses, releasing cytotoxic proteins and nitric
oxide, producing type 1 cytokines (IL-12 and IFN gamma) and
recruiting CD8+ T cells. Eosinophils also contribute to clearing
the viral load, insuring recovery from infection. Moreover, IL-
4/13s increase IgE production by B cells, further impairing the
activation of innate immune response. Increased expression of T2
cytokines, TGF-β and Suppressor Of Cytokine Signaling (SOCS)
1/3 negatively regulates type I IFN production, further increasing
the risk of viral infections (22, 23). However, some studies have
shown that asthma is not a risk factor in patients with COVID-
19 (3). In the study by Zhang et al., involving 140 community-
infected COVID-19 subjects, asthma was not reported by any
of the patients (24). Similarly, Dong et al., in a case series of
2,135 pediatric patients with COVID-19, did not report any case
of asthma (25). In the Confidence study, which included 100
pediatric patients with COVID-19, chronic respiratory diseases
did not appear as risk factors (26).
PROTECTIVE FACTORS AGAINST
SARS-COV-2 INFECTION IN CHILDREN
WITH ASTHMA
Some protective factors against SARS-COV-2 infection have
been hypothesized in patients with allergic asthma, such as T2
immune response (Figure 1), overproduction of mucus, and
asthma treatment (27–30).
Type 2 Immune Response
The T2 immune response in asthmatic patients might counteract
the COVID-19 cytokine storm (2). According to Kimura et al., in
airway epithelial cells of patients with allergic asthma ACE 2 is
reduced and TMPRSS2 is increased thanks to IL-13 exposure. In
addition, patients with activated Th2 immune responses showed
decreased expression of ACE 2 in airway epithelial cells, inversely
correlated with T2 cytokine levels and Th2 signature molecule
expression (31). In the study by Sajuthi et al., nasal airway
transcriptome and network co-expression analysis were used to
detect cellular and transcriptional factors of ACE 2 and TMPRSS2
genes in a cohort of 695 subjects with asthma and healthy
controls between 8 and 21 years of age. They found that Th2
inflammation had a major role in ACE 2 down-regulation as
well as in TMPRSS2 up-regulation. The study also showed that
ACE 2 expression was marked only in secretory cells and ciliated
cells, whereas TMPRSS2 was expressed in all epithelial cell types.
Overall, these results suggest that Th2 immune responses may
be a protective factor against SARS-COV-2 infection by causing
ACE 2 down-regulation (32). Additionally, since eosinopenia has
been observed in COVID-19 patients, the increased number of
eosinophils in asthmatic patients could have a protective role
against SARS-COV-2 (27). Though the relationship between
eosinophil levels and COVID-19 is still not clear, during the
pandemic it is important to monitor eosinophil counts and the
clinical course of COVID-19 in patients with asthma treated
with biological drugs responsible for decreased eosinophil levels
(33). Indeed, anti-IL-5 biologics such as mepolizumab reduce
eosinophils, and apparently could increase susceptibility to viral
infections (5).
Overproduction of Mucus
Mucus hypersecretion could be recognized as another
hypothetical protective factor against COVID-19 because
it acts as the first line of defense against infection, thereby
preventing SARS-COV-2 from reaching the distal airways and
entry into the alveolar type 2 cells, which predominantly express
ACE 2 in the lung. In asthma there is increased expression of
MUC5AC (34), which has been proved to give protection against
influenza infection in a murine model (35). However, not all
patients with asthma show mucus overproduction; thus, mucus
hyperproduction may only give protection in some patients.
Moreover, it should be recognized that other respiratory diseases
characterized by mucus hypersecretion like COPD showed poor
outcomes from SARS-COV-2 infection (29).
Asthma Treatment
Inhaled corticosteroids (ICS) are the first line treatment of
asthma. One study hypothesized that ICS could increase anti-
viral immunity in treated patients (27). There is also evidence that
ICS may down-regulate both ACE 2 and TMPRSS2 expression,
thereby decreasing binding of SARS-COV-2 to receptors
on the airway epithelium cells (12, 20, 30, 36). Moreover,
ICS suppress virus replication and cytokine production (28).
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FIGURE 1 | Impact of T2 immune response on SARS-COV-2 infection susceptibility and severity. T2 immune response inhibits SARS-COV-2 entry into the cell
through ACE2R down-regulation (red arrow) and helps to clear the viral load through activation of immune response orchestrated by eosinophils (green arrow).
Matsuyama et al. have demonstrated that ciclesonide blocks
SARS-COV-2 replication in vitro and inhibits its cytopathic
activity, reducing the severity of the disease. Additionally, the
combination of formoterol, glycopyrronium and budesonide
has been shown to inhibit seasonal coronavirus replication and
cytokine production (37). Peters et al. studied ACE 2 and
TMPRSS2 gene expression in sputum cells of 330 patients with
asthma and 79 healthy controls, finding that use of ICS was
associated with lower expression of ACE 2 and TMPRSS2 after
adjustment for asthma severity. Therefore, these data provided
further explanation about factors that may be responsible for the
low prevalence of asthma among COVID-19 patients. However,
it should be considered that though ACE 2 receptors are
particularly expressed in type 2 pneumocytes and sputum, this
may not reflect ACE 2 receptors levels in the lower airways.
Further, since the level of deposition of many ICS is low in
peripheral airways, they might not affect ACE 2 expression in
type 2 pneumocytes (12). Moreover, even though corticosteroids
are not considered a fundamental therapy for lung injury in
COVID-19 patients, it has been hypothesized that they may be
beneficial to suppress the cytokine storm typically associated with
the advanced phase of the disease (27).
Allergen immunotherapy (AIT) suppresses T2 immune
responses and controls allergic inflammation by stimulating
T regulator cell responses and preventing tissue homing and
degranulation of mast cells, basophils and eosinophils (38, 39).
Therefore, it could be supposed that AIT might play a role in
preventing a cytokine storm (2, 27).
In recent studies, the monoclonal antibody against human
IgE Omalizumab has been suggested to have a potential effect
on antiviral responses by reducing susceptibility to respiratory
virus infections (2, 27). The recently approved biologic drug,
Dupilumab, a human IgG4 antibody anti-IL-4 receptor (IL-4R)
α-subunit that blocks IL-4R signaling induced by both IL-4 and
IL-13, may also exert a protective role as it induces ACE 2
down-regulation (33, 40).
DISCUSSION
In spite of inadequate antiviral immune responses and
vulnerability to acute exacerbations due to viral infections, there
is evidence that asthmatics have reduced susceptibility to SARS-
COV-2 infection (2). Overall, this might be ascribed to specific
asthma-related factors such as T2 responses, overproduction
of mucus, asthma treatment along with behavioral factors not
strictly related to asthma, such as social distancing, hygiene
measures and wearing facemasks, helping to reduce individual
susceptibility to SARS-COV-2 infection (3, 27). Social distancing
and facemasks may decrease viral transmission from person
to person (41). Evidence suggests that adherence to preventive
measures is influenced by the perceived risk of infection. In
a cross-sectional study on adolescents with chronic diseases,
including asthma, 60% respondents reported high adherence
to preventive measures such as hand-washing, avoiding group
gatherings, reducing use of public transportation and avoiding
public places. The rate of adherence to preventive measures was
similar for respondents with and without chronic diseases (42).
However, evidence on young children is lacking. With regard
to facemasks, their use has been shown to reduce transmission
of coronaviruses and influenza viruses by blocking the release
of virions into the air (43). This is particularly relevant in
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children with asthma given that respiratory viruses are main
drivers of exacerbations (44). However, during the first wave
of the pandemic, children with asthma did not show severe
COVID-19 infection, regardless of asthma severity and control
(45). Moreover, improved childhood asthma outcomes were
observed, namely reduced acute attacks, emergency department
visits, and hospitalizations as well as improved scores in asthma
control measures and lung function. These findings might be
due to reduced exposure to outdoor asthma triggers, such as
seasonal allergens and air pollutants, and increased treatment
adherence (46–48).
Based on the available literature, COVID-19 outcomes vary
from mild to severe clinical manifestations and this may reflect
different airway levels of ACE 2 and TMPRSS2, which are
indispensable for virus entry into the host cell. Several authors
have hypothesized that in children with asthma T2 immune
response may lead to ACE 2 down-regulation and TMPRSS2 up-
regulation, thereby reducing the risk of illness due to SARS-COV-
2 (3, 18, 27). Additionally, a recent study involving children and
adults with asthma from three different cohorts demonstrated
that ACE 2 receptor levels were lower in patients with allergic
sensitization, whereas no association was found in patients
with non-atopic asthma (3, 27). Therefore, decreased ACE 2
expression may have an important role along with several other
factors in reducing COVID-19 severity in patients with allergic
asthma (3, 18, 27). As for blood eosinophil counts, reports
from China suggested that a worse prognosis of COVID-19
can be hypothesized when patients show severe eosinopenia
and lymphopenia. In addition, it has been hypothesized that
SARS-CoV-2 infection could be related to low eosinophil levels
in peripheral blood and that high blood eosinophil counts in
children with asthma could be a protective factor against SARS-
CoV-2. Nonetheless, others studies did not show low eosinophil
counts in patients with severe COVID-19 (49, 50). Though the
relationship between eosinophil levels and COVID-19 is still
uncertain, monitoring level of eosinophils in asthma patients
has been suggested, especially in those treated with biological
drugs that provoke a reduction of eosinophils in peripheral blood
(3, 27). In addition, some authors hypothesize that cytokines and
chemokines involved in T2 immune responses, like IL-13, IL-9
and Macrophage Inflammatory Protein-1 alpha and beta, might
counteract the pool of proinflammatory cytokines involved in the
pathogenesis of COVID-19. Since few data are available, other
studies are needed (2).
Overproduction of mucus in asthma has also been
suggested to have a protective role, since mucus, rich in
mucin glycoproteins, acts as the first line of defense against
viruses; however, further studies are needed to confirm this
hypothesis (29).
With regard to asthma treatment, evidence suggests that
ICS are associated with decreased ACE 2 and TMPRSS2 gene
expression and that taking ICS may be beneficial in treating
coronavirus infections (12). In particular, a study in vitro showed
that budesonide can inhibit HCoV-229E replication and cytokine
release, and demonstrated that SARS-CoV-2 RNA replication
and its cytopathic effects are blocked by ciclesonide, suggesting
a protective role against this virus (37). However, given the low
level of many ICS deposition in peripheral airways, they might
not affect ACE 2 expression in type 2 pneumocytes. Furthermore,
ICS may increase antiviral immunity which is typically inhibited
by T2 immune responses (12, 20, 27, 30, 37). Studies in vitro
demonstrated that glycopyrronium has an inhibitory effect
on seasonal coronavirus replications and cytokine production.
These effects are reinforced when glycopyrronium is used in
combination with formoterol and budesonide in vitro (27, 37).
Nonetheless, glycopirronium is not routinely used in children
and more studies are needed to better understand if asthma
treatment could really be considered protective against SARS-
COV-2 infection (27, 51).
Poor evidence is available about the role of AIT and biologic
drugs; it is possible that AIT is protective against the cytokine
storm occurring in severe COVID-19 by inducing a state
of immune tolerance. As for biologic drugs, some studies
hypothesized that Omalizumab may have a protective role
against viral infections that induce asthma exacerbations and
that Dupilumab may have a role against SARS-COV-2 as it
could reduce expression of ACE 2 (2, 27, 33). Therefore, in
light of the abovementioned data and according to the Global
Initiative for Asthma Guidelines (GINA) recommendations,
children with asthma should continue their treatment to prevent
asthma exacerbations due to SARS-COV-2 infection (1, 27, 52),
undergoing pulmonary function tests when needed to guide
management (53).
In summary, based on the available literature, whether asthma
could really be considered a protective condition against SARS-
COV-2 infection in children is still not clear. Therefore, further
studies are required to clarify the impact of asthma on COVID-
19 susceptibility and severity, especially in pediatric population
where the available evidence is very limited. Nonetheless,
parents and caregivers can be reassured that severe COVID-
19 infection is generally rare in children, irrespective of their
having asthma. Additionally, it should be pointed out that, even
in countries with a high number of COVID-19 infections, the
incidence of COVID-19 did not increase with the reopening
of schools and outbreaks in schools occurred uncommonly,
especially when precautions to control virus transmission
were taken (54).
AUTHOR CONTRIBUTIONS
ML and SL: conceptualization. ML and GF: writing original draft.
GF and SL: review and editing.
REFERENCES
1. Shukla SC. ACE2 expression in allergic airway disease may decrease the
risk and severity of COVID-19. Eur Arch Otorhinolaryngol. (2020) 6:1–4.
doi: 10.1007/s00405-020-06408-7
2. Liu S, Zhi Y, Ying S. COVID-19 and asthma: reflection during the pandemic.
Clin Rev Allergy Immunol. (2020) 59:78–88. doi: 10.1007/s12016-020-08797-3
3. Morais-Almeida M, Pité H, Aguiar R, Ansotegui I, Bousquet J. Asthma and
the coronavirus disease 2019 pandemic: a literature review. Int Arch Allergy
Immunol. (2020) 181:680–8. doi: 10.1159/000509057
Frontiers in Pediatrics | www.frontiersin.org 5 April 2021 | Volume 9 | Article 661206
Liuzzo Scorpo et al. Asthma and COVID-19 in Children
4. Chavasse R, Almario A, Christopher A, Kappos A, Shankar A. The indirect
impact of COVID-19 on children with asthma. Arch Bronconeumol. (2020)
56:768–9. doi: 10.1016/j.arbres.2020.07.003
5. Ciprandi G, Licari A, Filippelli G, Tosca MA, Marseglia GL. Children
and adolescents with allergy and/or asthma seem to be protected from
coronavirus disease 2019. Ann Allergy Asthma Immunol. (2020) 125:361–
2. doi: 10.1016/j.anai.2020.06.001
6. Frenkel LD, Gomez F, Bellanti JA. COVID-19 in children:
pathogenesis and current status. Allergy Asthma Proc. (2021) 42:8–15.
doi: 10.2500/aap.2021.42.200104
7. Moeller A, Thanikkel L, Duijts L, Gaillard EA, Garcia-Marcos L, Kantar
A, et al. COVID-19 in children with underlying chronic respiratory
diseases: survey results from 174 centres. ERJ Open Res. (2020) 6:00409-
2020. doi: 10.1183/23120541.00409-2020
8. Steinman JB, Lum FM, Ho PP-K, Kaminski N, Steinman L. Reduced
development of COVID-19 in children reveals molecular checkpoints gating
pathogenesis illuminating potential therapeutics. Proc Natl Acad Sci USA.
(2020) 117:24620–6. doi: 10.1073/pnas.2012358117
9. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-
converting enzyme 2 in children and adults. JAMA. (2020) 323:2427–
9. doi: 10.1001/jama.2020.8707
10. Palma J, Tokarz-Deptuła B, Deptuła J, Deptuła W. Natural antibodies
- facts known and unknown. Cent Eur J Immunol. (2018) 43:466–
75. doi: 10.5114/ceji.2018.81354
11. Carsetti R, Quintarelli C, Quinti I, Mortari EP, Zumla A, Ippolito
G, et al. The immune system of children: the key to understanding
SARS-CoV-2 susceptibility? Lancet Child Adolesc Health. (2020) 4:414–
6. doi: 10.1016/S2352-4642(20)30135-8
12. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery
MT, et al. COVID-19–related genes in sputum cells in asthma.
Relationship to demographic features and corticosteroids. Am J
Respir Crit Care Med. (2020) 202:83–90. doi: 10.1164/rccm.202003-
0821OC
13. Ozturk A. Angiotensin converting enzyme-2 (ACE2) receptors, asthma and
severe COVID-19 infection risk. Eur Ann Allergy Clin Immunol. (2020)
52:282–5. doi: 10.23822/EurAnnACI.1764-1489.169
14. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W,
Brüggen M-C, et al. Immune response to SARS-CoV-2 and mechanisms
of immunopathological changes in COVID-19. Allergy. (2020) 75:1564–
81. doi: 10.1111/all.14364
15. Garcia-Garcia ML, Rey CC, del Rosal Rabes T. Pediatric
asthma and viral infection. Arch Bronconeumol. (2016) 52:269–
73. doi: 10.1016/j.arbres.2015.11.008
16. Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr. (2018)
6:186. doi: 10.3389/fped.2018.00186
17. Ding B, Lu Y. A suggested approach for management of pediatric
asthma during the COVID-19 pandemic. Front Pediatr. (2020)
8:563093. doi: 10.3389/fped.2020.563093
18. Coverstone AM, Wang L, Sumino K. Beyond respiratory syncytial virus
and rhinovirus in the pathogenesis and exacerbation of asthma: the role of
metapneumovirus, bocavirus and influenza virus. Immunol Allergy Clin North
Am. (2019) 39:391–401. doi: 10.1016/j.iac.2019.03.007
19. Kumar K, Hinks TS, Singanayagam A. Treatment of COVID-19-
exacerbated asthma: should systemic corticosteroids be used? Am J
Physiol Lung Cell Mol Physiol. (2020) 318:L1244–7. doi: 10.1152/ajplung.
00144.2020
20. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood
RA, et al. Association of respiratory allergy, asthma, and expression of
the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. (2020) 146:203–
6.e3. doi: 10.1016/j.jaci.2020.04.009
21. Profita M, La Grutta S, Carpagnano E, Riccobono L, Di Giorgi R, Bonanno
A, et al. Noninvasive methods for the detection of upper and lower airway
inflammation in atopic children. J Allergy Clin Immunol. (2006) 118:1068–
74. doi: 10.1016/j.jaci.2006.07.028
22. Gagliardo R, Chanez P, Gjomarkaj M, La Grutta S, Bonanno A, Montalbano
A, et al. The role of transforming growth factor-β1 in airway inflammation
of childhood asthma. Int J Immunopathol Pharmacol. (2013) 26:725–
38. doi: 10.1177/039463201302600316
23. Wark PAB, Ramsahai JM, Pathinayake P, Malik B, Bartlett NW.
Respiratory viruses and asthma. Semin Respir Crit Care Med. (2018)
39:45–55. doi: 10.1055/s-0037-1617412
24. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical
characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
Allergy. (2020) 75:1730–41. doi: 10.1111/all.14238
25. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology
of COVID-19 among children in China. Pediatrics. (2020)
145:e20200702. doi: 10.1542/peds.2020-0702
26. Parri N, Lenge M, Buonsenso D. Children with Covid-19 in
pediatric emergency departments in Italy. N Engl J Med. (2020)
383:187–90. doi: 10.1056/NEJMc2007617
27. Hughes-Visentin A, Paul ABM. Asthma and COVID-19: what do
we know now. Clin Med Insights Circ Respir Pulm Med. (2020)
14:1179548420966242. doi: 10.1177/1179548420966242
28. Halpin DM, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-
19: a systematic review and clinical perspective. Eur Respir J. (2020)
55:2001009. doi: 10.1183/13993003.01009-2020
29. Farne H, Singanayagam A. Why asthma might surprisingly
protect against poor outcomes in COVID-19. Eur Respir J. (2020)
56:2003045. doi: 10.1183/13993003.03045-2020
30. Izquierdo JL, Almonacid C, González Y, Del Rio-Bermúdez C, Ancochea J,
Cárdenas R, et al. The impact of COVID-19 on patients with asthma. Eur
Respir J. (2020) 57:2003142. doi: 10.1183/13993003.03142-2020
31. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D,
Polverino F, et al. Type 2 inflammation modulates ACE2 and
TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. (2020)
146:80–8.e8. doi: 10.1016/j.jaci.2020.05.004
32. Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL,
et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry
factor expression in the airway epithelium. Nat Commun. (2020) 11:5139.
doi: 10.1038/s41467-020-18781-2
33. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda
LK, et al. COVID-19, asthma, and biologic therapies: what we need to know.
World Allergy Organ J. (2020) 13:100126. doi: 10.1016/j.waojou.2020.100126
34. Groneberg D, Eynott P, Lim S, Oates T, Wu R, Carlstedt I, et al.
Expression of respiratory mucins in fatal status asthmaticus and mild asthma.
Histopathology. (2002) 40:367–73. doi: 10.1046/j.1365-2559.2002.01378.x
35. Ehre C, Worthington EN, Liesman RM, Grubb BR, Barbier D, O’Neal
WK, et al. Overexpressing mouse model demonstrates the protective role
of Muc5ac in the lungs. Proc Natl Acad Sci USA. (2012) 109:16528–
33. doi: 10.1073/pnas.1206552109
36. Abrams EM, Sinha I, Fernandes RM, Hawcutt DB. Pediatric asthma
and COVID-19: the known, the unknown, and the controversial. Pediatr
Pulmonol. (2020) 55:3573–8. doi: 10.1002/ppul.25117
37. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The
inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting
the viral replication-transcription complex in cultured cells. J Virol. (2020)
95:e01648–20. doi: 10.1128/JVI.01648-20
38. Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos
NG, et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy.
(2019) 74:2087–102. doi: 10.1111/all.13805
39. Pajno GB, Bernardini R, Peroni D, Arasi S, Martelli A, Landi M, et al.
Clinical practice recommendations for allergen-specific immunotherapy
in children: the Italian consensus report. Ital J Pediatr. (2017)
43:13. doi: 10.1186/s13052-016-0315-y
40. Matsumoto K, Saito H. Does asthma affect morbidity or severity of COVID-
19? J Allergy Clin Immunol. (2020) 146:55–7. doi: 10.1016/j.jaci.2020.05.017
41. Mustafa SS, Shaker MS, Munblit D, Greenhawt M. Paediatric allergy practice
in the era of coronavirus disease 2019.Curr Opin Allergy Clin Immunol. (2021)
21:159–65. doi: 10.1097/ACI.0000000000000727
42. Yang XY, Gong RN, Sassine S, Morsa M, Tchogna AS, Drouin O, et al.
Risk perception of COVID-19 infection and adherence to preventive
measures among adolescents and young adults. Children. (2020)
7:311. doi: 10.3390/children7120311
43. Leung NHL, Chu DKW, Shiu EYC, Kwok-Hung C,McDevitt JJ, Hau BJP, et al.
Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat
Med. (2020) 26:676–80. doi: 10.1038/s41591-020-0843-2
Frontiers in Pediatrics | www.frontiersin.org 6 April 2021 | Volume 9 | Article 661206
Liuzzo Scorpo et al. Asthma and COVID-19 in Children
44. Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist
C, Bruno A, et al. Viruses and bacteria in acute asthma
exacerbations–a GA2 LEN-DARE systematic review. Allergy. (2011)
66:458–68. doi: 10.1111/j.1398-9995.2010.02505.x
45. Ruano FJ, Somoza Álvarez ML, Haroun-Díaz E, Vázquez de la Torre M, López
González P, Prieto-Moreno A, et al. Impact of the COVID-19 pandemic in
children with allergic asthma. J Allergy Clin Immunol Pract. (2020) 8:3172–
4. doi: 10.1016/j.jaip.2020.07.019
46. Kenyon CC, Hill DA, Henrickson SE, Bryant-Stephens TC, Zorc JJ.
Initial effects of the COVID-19 pandemic on pediatric asthma emergency
department utilization. J Allergy Clin Immunol Pract. (2020) 8:2774–
6. doi: 10.1016/j.jaip.2020.05.045
47. Krivec U, Kofol Seliger A, Tursic J. COVID-19 lockdown dropped the
rate of paediatric asthma admissions. Arch Dis Child. (2020) 105:809–
10. doi: 10.1136/archdischild-2020-319522
48. Papadopoulos NG, Mathioudakis AG, Custovic A, Deschildre A,
Phipatanakul W, Wong G, et al.; PeARL collaborators, on behalf of the
PeARL Think Tank. Childhood asthma outcomes during the COVID-19
pandemic: Findings from the PeARL multinational cohort. Allergy. (2021).
doi: 10.1111/all.14787
49. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al.
Covid-19 in critically ill patients in the Seattle region—case series. N Engl J
Med. (2020) 382:2012–22. doi: 10.1056/NEJMoa2004500
50. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics
of 3062 COVID-19 patients: a meta-analysis. J Med Virol. (2020) 92:1902–
14. doi: 10.1002/jmv.25884
51. Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF, Pace W, Schatz M.
Managing asthma in adolescents and adults: 2020 asthma guideline update
from the National Asthma Education and Prevention Program. JAMA. (2020)
324:2301–17. doi: 10.1001/jama.2020.21974
52. Cardinale F, Ciprandi G, Barberi S, Bernardini R, Caffarelli C, Calvani
M, et al. Consensus statement of the Italian society of pediatric
allergy and immunology for the pragmatic management of children and
adolescents with allergic or immunological diseases during the COVID-
19 pandemic. Ital J Pediatr. (2020) 46:84. doi: 10.1186/s13052-020-
00843-2
53. Bignamini E, Cazzato S, Cutrera R, Ferrante G, La Grutta S, Licari
A, et al. Italian pediatric respiratory society recommendations
on pediatric pulmonary function testing during COVID-19
pandemic. Ital J Pediatr. (2020) 46:68. doi: 10.1186/s13052-020-
00829-0
54. Boechat JL,Wandalsen GF, Kuschnir FC, Delgado L. COVID-19 and pediatric
asthma: clinical and management challenges. Int J Environ Res Public Health.
(2021) 18:1093. doi: 10.3390/ijerph18031093
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Liuzzo Scorpo, Ferrante and La Grutta. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pediatrics | www.frontiersin.org 7 April 2021 | Volume 9 | Article 661206
